Inhibikase Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Inhibikase Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$5.78M, a 25.7% decline year-over-year.
  • Inhibikase Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$19.6M, a 2.28% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$19M, a 5.4% decline from 2022.
  • Inhibikase Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.1M, a 22.1% decline from 2021.
  • Inhibikase Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$14.8M, a 419% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$19.6M -$5.78M -$1.18M -25.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$18.4M -$4.96M +$818K +14.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$19.2M -$4.65M -$172K -3.84% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$19M -$4.18M +$101K +2.36% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 -$19.1M -$4.6M -$101K -2.24% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$19M -$5.78M -$1.14M -24.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$17.9M -$4.48M +$163K +3.51% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$18.1M -$4.28M +$763K +15.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 -$18.8M -$4.49M -$23.4K -0.52% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$18.8M -$4.64M -$2M -76% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$16.8M -$4.64M -$2M -76% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$14.8M -$5.04M -$3.83M -317% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$11M -$4.47M -$3.8M -567% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$7.15M -$2.64M -$2.21M -525% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$4.94M -$2.64M -$2.09M -382% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$2.85M -$1.21M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$671K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$422K Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$547K Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.